Recently, the first batch of commercialized domestic cat vaccine Miosanto® was officially supplied and launched in Suzhou. Zoetis, a global animal health company, held the Zoetis China Biopharmaceutical Manufacturing Base and R&D Center in Suzhou (Zotis Biopharmaceutical Co., Ltd. ) opening activities. This marks a critical step for Zoetis' localized production in China and is an important milestone in Zoetis' long-term strategy of "based on China and serving China".
Miao Sanduo ® is a triple vaccine for cats under Zoetis. It was approved and registered by the Ministry of Agriculture and Rural Affairs of China (formerly the Ministry of Agriculture) in 2011 and entered the Chinese market. It can be used to prevent feline rhinotracheitis, calicivirus disease and panleukopenia. Jeff Pruis, Vice President of Zoetis Global Manufacturing and Supply Asia Pacific, said: "This time, our flagship product Miasado® is the first batch of commercial biological products delivered to the market by Zoetis Biopharmaceutical Co., Ltd. After it is put into production, the production capacity will better meet domestic needs. With the market demand for triple vaccine for cats, domestically produced Miosanduo® will create greater value for Chinese partners and customers."
Jeff Pruis further said, "Zoetis focuses on continuous innovation in animal health, and R&D is an important part of the enterprise. The core source of sustainable development. With the support of Zoetis' global network, equipped with world-class equipment and high-standard process control, Zoetis China team will ensure that the factory in Suzhou Park produces and supplies consistent high-quality products and builds a high-value production factory , to promote the development and growth of China's cat vaccine industry."
Zotis Global CEO Kristin Peck congratulated and delivered a speech via video: "As one of the largest markets in the world, China contains huge potential and has a unique market Environment. The completion of Zoetis Biopharmaceutical Co., Ltd.'s manufacturing base and R&D center in Suzhou is a strong proof of our continued investment in talents and local innovation in China. It also demonstrates the synergy of the integration of research, production and marketing. I believe that the manufacturing base and R&D center It will add strong impetus to Zoetis' future growth in China."
It is reported that the opening of the manufacturing base and R&D center of Zoetis Biopharmaceutical Co., Ltd. is an important milestone for Zoetis since its investment and construction in Suzhou Industrial Park in 2017. It is also the " An important practice of the long-term strategy of "Based on China and Serving China". Christophe Derozier, Vice President of Zoetis Global Veterinary Drug R&D, said in a video speech: "This manufacturing base and R&D center includes two major business segments: vaccine manufacturing and R&D. The one-stop layout of R&D and production will help Zoetis' global R&D headquarters' professional knowledge and The resource integration of China's local R&D technology builds a bridge from laboratory to commercial production for new products, accelerates product launch, and better meets market demand."
In the future, Zoetis will continue to devote itself to local product innovation, manufacturing technology upgrades and process improvements , providing the Chinese market with products that are as safe, effective and high-quality as the domestic Miao Sanduo®. Relying on Zoetis China's Beijing and Suzhou R&D centers, we will accelerate the entry of global diversified innovative products into China, further meet local market demand, and empower the development of China's animal health and medical industry.
